Compounds > y 26611
Page last updated: 2024-12-07

y 26611

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-(2-aminomethylmorpholino)-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132781
CHEMBL ID29572
SCHEMBL ID10511660
MeSH IDM0209370

Synonyms (14)

Synonym
7-(2-aminomethylmorpholino)-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
3-quinolinecarboxylic acid, 7-(2-(aminomethyl)-4-morpholinyl)-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-, (+-)-
7-ammcifq
146805-34-7
y-26611
y 26611
CHEMBL29572
7-[2-(aminomethyl)morpholin-4-yl]-1-cyclopropyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
143375-60-4
SCHEMBL10511660
AKOS030559210
7-[2-(aminomethyl)morpholin-4-yl]-1-cyclopropyl-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
DTXSID20931847
7-(2-(aminomethyl)morpholino)-1-cyclopropyl-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.507510.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.507510.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.507510.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.505710.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.497310.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.507510.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.498810.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.504610.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.507510.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.507510.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.507510.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.506510.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.505710.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.507510.0000AID71980; AID71981
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.507510.0000AID71980; AID71981
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.507510.0000AID71980; AID71981
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID131701Effective dose against Staphylococcus aureus smith strain in mouse1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID202106Minimum inhibition concentration against Streptococcus pneumoniae Type I strain1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID71794Percentage of GABA-induced chloride currents with 10e-4 M 4-biphenylacetic acid1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID151670Minimum inhibition concentration against Pseudomonas aeruginosa U-31 strain1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID65384Minimum inhibition concentration against Enterococcus faecalis LS-101 strain1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID28851The compound was evaluated for the solubility in water at 25 degrees Centigrade1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID71981Inhibition of [3H]muscimol binding to GABA A receptor with compound alone at 10 e-4 M1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID71980Inhibition of [3H]muscimol binding to GABA A receptor 4-biphenylacetic acid at 10 e-4 M1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID201090Minimum inhibitory concentration against Staphylococcus aureus Smith1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID131700Effective dose against Escherichia coli KC14 strain in mouse1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID110152Percentage of mice with convulsion (400 mg/kg fenbufen)1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID65203Minimum inhibitory concentration against Escherichia coli KC14 strain1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID65221Minimum inhibition concentration against Escherichia coli NIHJ JC-2 strain1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID28899Calculated partition coefficient (clogP)1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID125506The ratio of the number of Mongolian gerbils in which Helicobacter pylori was not detected to that of Mongolian gerbils tested (percent) was represented as clearance rate1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.
AID87939In vitro minimum inhibitory concentration against growth of Helicobacter pylori ATCC 43504.1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.
AID110153Percentage of mice with convulsion with compound alone at 400 mg/kg1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID71795Percentage of GABA-induced chloride currents with compound alone at 10 e-4 M1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID71793Percentage of GABA-induced chloride currents with 10 e-5 M 4-biphenylacetic acid1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID197875Minimum inhibition concentration against Staphylococcus aureus FDA209P strain1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.3820aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		1.9910aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		1.9810fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		2.68303-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
tosufloxacin
tosufloxacin: quinolone anti-infective agent; structure given in first source. tosufloxacin : A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin.. 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively.		1.99101,8-naphthyridine derivative;
amino acid;
aminopyrrolidine;
monocarboxylic acid;
organofluorine compound;
primary amino compound;
quinolone antibiotic;
tertiary amino compound
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		3.0850monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		1.9910penicillin allergen;
penicillin		antibacterial drug
ng-nitroarginine methyl ester
NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.		1.9910alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
sparfloxacin
[no description available]		1.9910fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		1.9910macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
8-fluorociprofloxacin
8-fluorociprofloxacin: structure given in first source		1.9810
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		1.99109-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
beta carotene
beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.		1.9910carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Helicobacter
[description not available]		01.9910
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		01.9910
Contact Dermatitis
[description not available]		01.9810
Experimental Radiation Injuries
[description not available]		01.9810
Dermatitis, Contact
A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.		01.9810
Actinic Reticuloid Syndrome
[description not available]		01.9910
Erythema
Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.		01.9910